A human-STING specific macrocyclic peptide suppresses cGAS-STING-induced inflammation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41290486.
- Also identified by DOI 10.1016/j.ard.2025.10.023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Suppression of hyperactive stimulator of interferon genes (STING) may provide therapeutic benefits to treat inflammatory diseases. We identified a macrocyclic peptide, named P1, which binds to human STING (hSTING) by a new platform for the discovery of pseudonatural macrocyclic peptides. In cellular experiments, P1 effectively blocked the translocation of hSTING from endoplasmic reticulum (ER) to the trans-Golgi network, increasing the accumulation of hSTING on ER, and thus interrupted the downstream STING signalling transduction, which resulted in reduced production of interferon-β (IFN-β) and proinflammatory cytokines, the major effectors of the STING pathway. Mechanistically, the crystallographic structure of P1-bound hSTING reveals that P1 binds to the cyclic nucleotides binding domain of hSTING dimers, the same domain as 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) (2'3'-cGAMP) binds, and that P1-bound hSTING dimers are trapped in an 'open' conformation due to 38°-rotated wings compared with the 'closed' conformation associated with 2'3'-cGAMP-mediated hSTING activation. Nano-P1, the nanoparticle form to increase its cellular membrane permeability, dampened the infectious inflammation induced by herpes simplex virus type 1 both in human cells and in humanised-STING (hSTING<sup>+/+</sup>) mice. Trex1-deficient hSTING<sup>+/+</sup> mice, which develop uncontrolled type I interferon-driven inflammation with growth failure and early lethality, were used to assess the effects of STING inhibition. Treatment with Nano-P1 suppressed the systemic inflammation, restored the regular growth, and substantially extended the survival of the otherwise runt and short-lived mice. Furthermore, neither in vitro nor in vivo experiments showed toxicity of Nano-P1, proving its safety for potential clinical application. Therefore, the macrocyclic peptide-based Nano-P1, an hSTING inhibitor, has great potential for treating the inflammation resulting from hyperactive STING.